Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D00SUK
|
||||
Former ID |
DNC010457
|
||||
Drug Name |
Tonapofylline
|
||||
Drug Type |
Small molecular drug
|
||||
Structure |
Download2D MOL |
||||
Formula |
C22H32N4O4
|
||||
InChI |
InChI=1S/C22H32N4O4/c1-3-13-25-17-16(18(29)26(14-4-2)20(25)30)23-19(24-17)22-10-7-21(8-11-22,9-12-22)6-5-15(27)28/h3-14H2,1-2H3,(H,23,24)(H,27,28)
|
||||
InChIKey |
ZWTVVWUOTJRXKM-UHFFFAOYSA-N
|
||||
PubChem Compound ID | |||||
PubChem Substance ID | |||||
Target and Pathway | |||||
Target(s) | Adenosine A1 receptor | Target Info | Inhibitor | [530752] | |
Adenosine A2b receptor | Target Info | Inhibitor | [530752] | ||
Adenosine A2a receptor | Target Info | Inhibitor | [530752] | ||
Adenosine A3 receptor | Target Info | Inhibitor | [530752] | ||
KEGG Pathway | cGMP-PKG signaling pathway | ||||
cAMP signaling pathway | |||||
Sphingolipid signaling pathway | |||||
Neuroactive ligand-receptor interaction | |||||
Morphine addictionhsa04015:Rap1 signaling pathway | |||||
Calcium signaling pathway | |||||
Vascular smooth muscle contraction | |||||
Alcoholismhsa04015:Rap1 signaling pathway | |||||
Parkinson's disease | |||||
Alcoholism | |||||
Pathway Interaction Database | C-MYB transcription factor networkhif2pathway:HIF-2-alpha transcription factor network | ||||
References | |||||
Ref 522369 | ClinicalTrials.gov (NCT00709865) Phase 2b Study to Assess the Safety and Tolerability of IV Tonapofylline in Subjects With Acute Decompensated Heart Failure (ADHF) and Renal Insufficiency. U.S. National Institutes of Health. | ||||
Ref 540973 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5605). |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.